<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Posts | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>Posts</span>
        <span>2024-10-26</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://deepin-community.github.io/sig-dde-porting/posts/dde-qt6.8-porting-guide/?utm_source=atom_feed">DDE Qt 6.8 适配说明</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/deepin-community-github-io-sig-dde-porting-posts-dde-qt6-8-porting-guide-utm-source-atom-feed/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450445/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Guidelines for the Prophylaxis and Treatment of Peritoneal Metastases From Colorectal Cancer: A GRADE-Approach for Evidence Evaluation and Recommendations</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450445-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Colorectal peritoneal metastases (CPM) are common in colorectal cancer patients. This article aims to provide GRADE guidelines for the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in two clinical situations: (1) To determine the value of adjuvant HIPEC for the prevention of CPM in high-risk colorectal cancer patients; (2) to determine the impact on survival of cytoreductive surgery and HIPEC followed by adjuvant systemic chemotherapy as compared to systemic chemotherapy alone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450445/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Guidelines for the Prophylaxis and Treatment of Peritoneal Metastases From Colorectal Cancer: A GRADE-Approach for Evidence Evaluation and Recommendations</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450445-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Colorectal peritoneal metastases (CPM) are common in colorectal cancer patients. This article aims to provide GRADE guidelines for the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in two clinical situations: (1) To determine the value of adjuvant HIPEC for the prevention of CPM in high-risk colorectal cancer patients; (2) to determine the impact on survival of cytoreductive surgery and HIPEC followed by adjuvant systemic chemotherapy as compared to systemic chemotherapy alone &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450725/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Specific Morphology of Coronary Artery Aneurysms in Mainly White Patients With Kawasaki Disease: Initial Data From the Cardiac Catheterization in Kawasaki Disease Registry</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450725-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: That distal CAAs were only present together with proximal ones will hopefully reduce diagnostic CCs in patients with KD without echocardiographically detected proximal CAAs. Furthermore, this study gives valuable insights into dimensional specifics of CAAs in patients with KD. As an ongoing registry, future analyses will further explore long-term outcomes and performed treatments, helping to refine clinical long-term strategies for patients with &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450725/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Specific Morphology of Coronary Artery Aneurysms in Mainly White Patients With Kawasaki Disease: Initial Data From the Cardiac Catheterization in Kawasaki Disease Registry</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450725-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: That distal CAAs were only present together with proximal ones will hopefully reduce diagnostic CCs in patients with KD without echocardiographically detected proximal CAAs. Furthermore, this study gives valuable insights into dimensional specifics of CAAs in patients with KD. As an ongoing registry, future analyses will further explore long-term outcomes and performed treatments, helping to refine clinical long-term strategies for patients with &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450752/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Microvascular Inflammation of Kidney Allografts and Clinical Outcomes</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450752-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Microvascular inflammation in kidney allografts includes distinct phenotypes, with various disease progression and allograft outcomes. Our findings support the clinical use of additional rejection phenotypes to standardize diagnostics for kidney allografts. (Funded by OrganX. ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450752/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Microvascular Inflammation of Kidney Allografts and Clinical Outcomes</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450752-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Microvascular inflammation in kidney allografts includes distinct phenotypes, with various disease progression and allograft outcomes. Our findings support the clinical use of additional rejection phenotypes to standardize diagnostics for kidney allografts. (Funded by OrganX. ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450752/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241025210305&amp;v=2.18.0.post9&#43;e462414">Microvascular Inflammation of Kidney Allografts and Clinical Outcomes</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450752-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241025210305-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Microvascular inflammation in kidney allografts includes distinct phenotypes, with various disease progression and allograft outcomes. Our findings support the clinical use of additional rejection phenotypes to standardize diagnostics for kidney allografts. (Funded by OrganX. ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450752/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241026190548&amp;v=2.18.0.post9&#43;e462414">Microvascular Inflammation of Kidney Allografts and Clinical Outcomes</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450752-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241026190548-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Microvascular inflammation in kidney allografts includes distinct phenotypes, with various disease progression and allograft outcomes. Our findings support the clinical use of additional rejection phenotypes to standardize diagnostics for kidney allografts. (Funded by OrganX. ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450797/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Development of the EULAT eCollect application for electronic data collection within the European-Latin American consortium towards eradication of preventable gallbladder cancer - EULAT Eradicate GBC</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450797-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The European-Latin American Consortium towards Eradication of Preventable Gallbladder Cancer (GBC) - EULAT Eradicate CVB is collecting high-quality data and samples in four Latin American countries with a high incidence of GBC: Argentina, Bolivia, Chile and Peru. The goal is to build a unique biorepository integrated with a customized informatics platform, identify, validate, and functionally characterize novel GBC risk biomarkers, and develop GBC prediction models integrating &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450797/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Development of the EULAT eCollect application for electronic data collection within the European-Latin American consortium towards eradication of preventable gallbladder cancer - EULAT Eradicate GBC</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450797-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The European-Latin American Consortium towards Eradication of Preventable Gallbladder Cancer (GBC) - EULAT Eradicate CVB is collecting high-quality data and samples in four Latin American countries with a high incidence of GBC: Argentina, Bolivia, Chile and Peru. The goal is to build a unique biorepository integrated with a customized informatics platform, identify, validate, and functionally characterize novel GBC risk biomarkers, and develop GBC prediction models integrating &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450931/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Cortisol dynamics and GR-dependent feedback regulation in zebrafish larvae exposed to repeated stress</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450931-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Zebrafish larvae show a rapid increase in cortisol in response to acute stressors, followed by a decline. While these responses are documented, both the duration of the refractory period to repeated stressors and the role of glucocorticoid receptors (GR) in specific phases of the glucocorticoid negative feedback are still being clarified. We explored these questions using water vortices as stressors, combined with GR blockage and measurements of whole-body cortisol in zebrafish larvae &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39450931/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Cortisol dynamics and GR-dependent feedback regulation in zebrafish larvae exposed to repeated stress</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39450931-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Zebrafish larvae show a rapid increase in cortisol in response to acute stressors, followed by a decline. While these responses are documented, both the duration of the refractory period to repeated stressors and the role of glucocorticoid receptors (GR) in specific phases of the glucocorticoid negative feedback are still being clarified. We explored these questions using water vortices as stressors, combined with GR blockage and measurements of whole-body cortisol in zebrafish larvae &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451122/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Overcoming Communication Barriers in Clinical Care: A Digital Translation Platform</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451122-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The pilot study demonstrates the feasibility of the Translatly platform in real-world healthcare settings. It shows potential to improve communication and patient outcomes by addressing language barriers. Despite its potential, challenges such as translator availability highlight the need for further &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451122/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Overcoming Communication Barriers in Clinical Care: A Digital Translation Platform</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451122-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The pilot study demonstrates the feasibility of the Translatly platform in real-world healthcare settings. It shows potential to improve communication and patient outcomes by addressing language barriers. Despite its potential, challenges such as translator availability highlight the need for further &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451370/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Nuclei Detection and Segmentation of Histopathological Images Using a Feature Pyramidal Network Variant of a Mask R-CNN</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451370-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Cell nuclei interpretation is crucial in pathological diagnostics, especially in tumor specimens. A critical step in computational pathology is to detect and analyze individual nuclear properties using segmentation algorithms. Conventionally, a semantic segmentation network is used, where individual nuclear properties are derived after post-processing a segmentation mask. In this study, we focus on showing that an object-detection-based instance segmentation network, the Mask R-CNN, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451370/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Nuclei Detection and Segmentation of Histopathological Images Using a Feature Pyramidal Network Variant of a Mask R-CNN</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451370-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Cell nuclei interpretation is crucial in pathological diagnostics, especially in tumor specimens. A critical step in computational pathology is to detect and analyze individual nuclear properties using segmentation algorithms. Conventionally, a semantic segmentation network is used, where individual nuclear properties are derived after post-processing a segmentation mask. In this study, we focus on showing that an object-detection-based instance segmentation network, the Mask R-CNN, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451431/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">The Use of Social Media in Orthopedic and Trauma Surgery Education: A Cross-Sectional Survey of German-Speaking Residents and Medical Students</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451431-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Orthopedic residents and students are high-volume social media users but engage more passively with professional content. While most value educational material, concerns about privacy violations and inappropriate posts remain &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451431/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">The Use of Social Media in Orthopedic and Trauma Surgery Education: A Cross-Sectional Survey of German-Speaking Residents and Medical Students</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451431-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Orthopedic residents and students are high-volume social media users but engage more passively with professional content. While most value educational material, concerns about privacy violations and inappropriate posts remain &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451658/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Inflammatory Signals Across the Spectrum: A Detailed Exploration of Acute Appendicitis Stages According to EAES 2015 Guidelines</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451658-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Background: In this retrospective study, we evaluate the diagnostic utility of C-reactive protein (CRP) and leucocyte count within the EAES 2015 guidelines for acute appendicitis (AA) in differentiating uncomplicated (UAA) from complicated AA (CAA). Methods: Conducted at a tertiary care center in Germany, the study included 285 patients over 18 years who were diagnosed with AA from January 2019 to December 2021. Patient data included demographics, inflammatory markers, and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39451658/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Inflammatory Signals Across the Spectrum: A Detailed Exploration of Acute Appendicitis Stages According to EAES 2015 Guidelines</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39451658-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Background: In this retrospective study, we evaluate the diagnostic utility of C-reactive protein (CRP) and leucocyte count within the EAES 2015 guidelines for acute appendicitis (AA) in differentiating uncomplicated (UAA) from complicated AA (CAA). Methods: Conducted at a tertiary care center in Germany, the study included 285 patients over 18 years who were diagnosed with AA from January 2019 to December 2021. Patient data included demographics, inflammatory markers, and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452517/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Validation of the Short Parallel and Extra-Short Form of the Heidelberg Figural Matrices Test (HeiQ)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452517-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Figural matrices tests are frequently used to measure fluid intelligence. The HeiQ-an operation-oriented figural matrices test-was developed to tackle limitations of previous matrices tests, mainly the possibility of excluding distractors based on superficial features instead of actively solving the items. However, allowing for a total administration time of 60 min for the assessment of one construct is not feasible in many study designs. Thus, the goal of this study was to develop three &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452517/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Validation of the Short Parallel and Extra-Short Form of the Heidelberg Figural Matrices Test (HeiQ)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452517-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Figural matrices tests are frequently used to measure fluid intelligence. The HeiQ-an operation-oriented figural matrices test-was developed to tackle limitations of previous matrices tests, mainly the possibility of excluding distractors based on superficial features instead of actively solving the items. However, allowing for a total administration time of 60 min for the assessment of one construct is not feasible in many study designs. Thus, the goal of this study was to develop three &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452571/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452571-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Many pwCF under ETI therapy have Cmax values for elexacaftor and ivacaftor above the recommended range, even on reduced doses or before the tmax was reached. This highlights the value of a TDM program. Further pharmacokinetic studies are &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452571/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452571-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Many pwCF under ETI therapy have Cmax values for elexacaftor and ivacaftor above the recommended range, even on reduced doses or before the tmax was reached. This highlights the value of a TDM program. Further pharmacokinetic studies are &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452767/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Association of Antibody Responses to &lt;em&gt;Helicobacter pylori&lt;/em&gt; Proteins with Colorectal Adenoma and Colorectal Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452767-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Helicobacter pylori (H. pylori) has been implicated in colorectal carcinogenesis. Here, the association of immune responses to bacterial exposure with advancing stages of colorectal neoplasia was assessed by multiplex serology. Immunoglobulin (Ig) A and G antibody responses to thirteen proteins of H. pylori were measured by a Luminex-based multiplex assay in plasma from patients with colorectal cancer (CRC, n = 25), advanced adenoma (n = 82), or small polyps (n = 85) and controls (n = &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452767/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Association of Antibody Responses to &lt;em&gt;Helicobacter pylori&lt;/em&gt; Proteins with Colorectal Adenoma and Colorectal Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452767-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Helicobacter pylori (H. pylori) has been implicated in colorectal carcinogenesis. Here, the association of immune responses to bacterial exposure with advancing stages of colorectal neoplasia was assessed by multiplex serology. Immunoglobulin (Ig) A and G antibody responses to thirteen proteins of H. pylori were measured by a Luminex-based multiplex assay in plasma from patients with colorectal cancer (CRC, n = 25), advanced adenoma (n = 82), or small polyps (n = 85) and controls (n = &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452778/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Cats: The New Challenge for Rabies Control in the State of Yucatan, Mexico</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452778-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The growing population in Yucatan has led to the expansion of construction in the Mayan jungle for tourist spaces, residential areas, and agriculture. Recently, rabies cases in cats (Felis catus) have increased in the state. This study aimed to perform antigenic and genetic characterization of the rabies viruses in felines and to present the spatial distribution and environmental features of the areas where these cases were reported. The ArcGIS software and R were employed to generate &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39452778/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Cats: The New Challenge for Rabies Control in the State of Yucatan, Mexico</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39452778-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The growing population in Yucatan has led to the expansion of construction in the Mayan jungle for tourist spaces, residential areas, and agriculture. Recently, rabies cases in cats (Felis catus) have increased in the state. This study aimed to perform antigenic and genetic characterization of the rabies viruses in felines and to present the spatial distribution and environmental features of the areas where these cases were reported. The ArcGIS software and R were employed to generate &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453356/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453356-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors may be more effective than GLP-1 receptor agonism alone in reducing body weight, but the cardiovascular (CV) effects are unknown. The authors describe the rationale and design of SYNCHRONIZE-CVOT, a phase 3, randomized, double-blind, parallel-group, event-driven, CV safety study of survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly compared with placebo in adults with a body &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453356/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453356-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors may be more effective than GLP-1 receptor agonism alone in reducing body weight, but the cardiovascular (CV) effects are unknown. The authors describe the rationale and design of SYNCHRONIZE-CVOT, a phase 3, randomized, double-blind, parallel-group, event-driven, CV safety study of survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly compared with placebo in adults with a body &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453357/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453357-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Hyperuricemia is a common complication in HFpEF and is related to advanced disease severity and adverse outcome. Empagliflozin induced a rapid and sustained reduction of SUA levels and of clinical events related to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453357/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453357-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Hyperuricemia is a common complication in HFpEF and is related to advanced disease severity and adverse outcome. Empagliflozin induced a rapid and sustained reduction of SUA levels and of clinical events related to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453489/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Palliative neurology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453489-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Palliative medicine represents the holistic multiprofessional treatment of severely and incurably ill people and their relatives, addressing their complex physical, psychological, social and spiritual needs. The central therapeutic goals are the quality of life and alleviation of suffering. In the course of many neurological diseases, high symptom burden, long and variable trajectories and unfavorable prognosis at times create a need for palliative care even at an early stage, which is &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453489/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Palliative neurology</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453489-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Palliative medicine represents the holistic multiprofessional treatment of severely and incurably ill people and their relatives, addressing their complex physical, psychological, social and spiritual needs. The central therapeutic goals are the quality of life and alleviation of suffering. In the course of many neurological diseases, high symptom burden, long and variable trajectories and unfavorable prognosis at times create a need for palliative care even at an early stage, which is &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453520/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Correction to: The role of resection in hepatocellular carcinoma BCLC stage B: A multi-institutional patient-level meta-analysis and systematic review</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453520-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453520/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Correction to: The role of resection in hepatocellular carcinoma BCLC stage B: A multi-institutional patient-level meta-analysis and systematic review</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453520-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453658/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Testosterone and Quality of Life in Transgender and Gender-Diverse Adults Seeking Masculinization: A Secondary Analysis of a Randomized Clinical Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453658-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453658/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Testosterone and Quality of Life in Transgender and Gender-Diverse Adults Seeking Masculinization: A Secondary Analysis of a Randomized Clinical Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453658-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453683/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453683-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: TaqMan array card measurements were found to be biologically valid and technically reproducible. The BioPac multianalyte marker panel is capable of sensitive and accurate detection of recurrence in patients resected for PDAC using a simple blood test. This could allow a closer follow-up using shorter time intervals than currently used for imaging, thus potentially prompting an earlier work-up with additional modalities to allow for earlier therapeutic intervention. This &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453683/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453683-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: TaqMan array card measurements were found to be biologically valid and technically reproducible. The BioPac multianalyte marker panel is capable of sensitive and accurate detection of recurrence in patients resected for PDAC using a simple blood test. This could allow a closer follow-up using shorter time intervals than currently used for imaging, thus potentially prompting an earlier work-up with additional modalities to allow for earlier therapeutic intervention. This &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453757/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241025210305&amp;v=2.18.0.post9&#43;e462414">Way Stations in Progress - Burgeoning Treatment Options for IgA Nephropathy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453757-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241025210305-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453757/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241026190548&amp;v=2.18.0.post9&#43;e462414">Way Stations in Progress - Burgeoning Treatment Options for IgA Nephropathy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453757-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241026190548-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453772/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241025210305&amp;v=2.18.0.post9&#43;e462414">Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453772-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241025210305-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with IgA nephropathy, treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453772/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241026190548&amp;v=2.18.0.post9&#43;e462414">Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453772-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241026190548-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with IgA nephropathy, treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453837/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241025210316&amp;v=2.18.0.post9&#43;e462414">Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453837-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241025210316-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In a broad range of patients with chronic kidney disease at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453837/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241026190550&amp;v=2.18.0.post9&#43;e462414">Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453837-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241026190550-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In a broad range of patients with chronic kidney disease at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453837/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241025210305&amp;v=2.18.0.post9&#43;e462414">Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453837-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241025210305-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In a broad range of patients with chronic kidney disease at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39453837/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241026190548&amp;v=2.18.0.post9&#43;e462414">Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39453837-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241026190548-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In a broad range of patients with chronic kidney disease at risk for progression, empagliflozin continued to have additional cardiorenal benefits for up to 12 months after it was discontinued. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EuDRACT number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OD8NCsoK0">这两天做文献综述，看到四年内LEN化学合成发了Science，preclinical发了Nature，治疗CAPELLA发了NEJM，PrEP发了NEJM（这些我微博都写过，但从没连起来读过）。工...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-od8ncsok0/">
    
    
    
    
    
      
    
    这两天做文献综述，看到四年内LEN化学合成发了Science，preclinical发了Nature，治疗CAPELLA发了NEJM，PrEP发了NEJM（这些我微博都写过，但从没连起来读过）。工业界越来越重视发顶刊，FDA和CDC越来越把peer reviewed顶刊当作审批和指南标准，因为它们都相信顶刊信誉，这是出版业蔓延到工业界的表现。  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1655755343/OD8WQCe6w">#四合如意##哀眠#工作七年后的一次答辩[求饶]创作之神三更授法，二十四友耳提面命[打call] - 转发 @复旦创意写作:&amp;ensp;欢迎大家来！会议预告 | 冲出日常——张...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1655755343-od8wqce6w/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted -->#四合如意#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#哀眠#<!-- raw HTML omitted --><!-- raw HTML omitted -->工作七年后的一次答辩<!-- raw HTML omitted -->&lt;img alt=&quot;[求饶]&quot; src=&ldquo;<a href="https://h5.sinaimg.cn/m/emoticon/icon/default/fb_a2qiurao-7ad34b9c84.png%22">https://h5.sinaimg.cn/m/emoticon/icon/default/fb_a2qiurao-7ad34b9c84.png&quot;</a> style=&ldquo;width:1em; height:1em;&rdquo; referrerpolicy=&ldquo;no-ref &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1655755343/ODcgHjJ5W">今天小说写作实践两组素材展示都很棒，四次亚军的女围棋手，跨国消失的少女及后来呢[笑cry] [图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1655755343-odcghjj5w/">
    
    
    
    
    
      
    
    今天小说写作实践两组素材展示都很棒，四次亚军的女围棋手，跨国消失的少女及后来呢<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/62b0d24fgy1huys9nf2hxj21400u0dnh.jpg%22">https://tvax4.sinaimg.cn/large/62b0d24fgy1huys9nf2hxj21400u0dnh.jpg&quot;</a> referrerpolicy=&ldquo;no-re &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1655755343/ODcp8tM21">[笑cry]这周也有同学阅读作业写雪梨·杰克逊的《盐柱》 - 转发 @Evian一朵:&amp;ensp;刚刚看完怡微老师@张怡微 在小说界发表的新短篇《看见盐柱的寻常一天》，最初知...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1655755343-odcp8tm21/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->这周也有同学阅读作业写雪梨·杰克逊的《盐柱》<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@Evian一朵<!-- raw HTML omitted -->: 刚刚看完怡微老师<!-- raw HTML omitted -->@张怡微<!-- raw HTML omitted --> 在小说界发表的新短篇《看见盐柱的寻常一天》，最初知晓篇名时想到了雪梨·杰克逊，直至在后记读到老师引余光中的诗句才知，这里还有老师匠心独 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeCD8Wzl">🔻黎巴嫩媒体援引真主党发布的新视频：在黎巴嫩边境附近的扎里特定居点，真主党武装使用钻石线导反坦克导弹，打掉以军一辆梅卡瓦坦克。🔻可以看到，射击距离...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odecd8wzl/">
    
    
    
    
    
      
    
    🔻黎巴嫩媒体援引真主党发布的新视频：在黎巴嫩边境附近的扎里特定居点，真主党武装使用钻石线导反坦克导弹，打掉以军一辆梅卡瓦坦克。<!-- raw HTML omitted -->🔻可以看到，射击距离相当远，导弹飞跃一个山丘到达高点，再攻顶袭击了以军坦克。<!-- raw HTML omitted -->🔻战斗时间是10月19日。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#巴勒斯坦女孩被当作人肉盾牌探路 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeFUbkeF">🔻之前我说朝鲜大城市能用扫码付款，有些网友不信。🔻这是赵代表在平壤的亲身体验，真的能扫。 [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odefubkef/">
    
    
    
    
    
      
    
    🔻之前我说朝鲜大城市能用扫码付款，有些网友不信。<!-- raw HTML omitted -->🔻这是赵代表在平壤的亲身体验，真的能扫。 <!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeH8FW2G">🔻斯拉夫大区日常。 包容万物恒河水的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odeh8fw2g/">
    
    
    
    
    
      
    
    🔻斯拉夫大区日常。 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->包容万物恒河水的微博视频<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/1xwsXRmvlx08j4L0Od0k010412005cqG0E010.mp4?labe">https://f.video.weibocdn.com/o0/1xwsXRmvlx08j4L0Od0k010412005cqG0E010.mp4?labe</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeIRdE0h">🔻大量美军加油机正在飞行。🔻via ads-b ex#巴勒斯坦女孩被当作人肉盾牌探路# [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odeirde0h/">
    
    
    
    
    
      
    
    🔻大量美军加油机正在飞行。<!-- raw HTML omitted -->🔻via ads-b ex<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#巴勒斯坦女孩被当作人肉盾牌探路#<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/639b1bfbly1huz32pvt1gj20u00kfn9t.jpg%22">https://tvax4.sinaimg.cn/large/639b1bfbly1huz32pvt1gj20u00kfn9t.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeMl2UXi">🔻这是这些天美国大选讨论中，美国网友回忆的“美国梦”。🔻图1（1947年），俄克拉荷马州塔尔萨，参加派对的青少年。🔻图2（1947年），家庭主妇与一周的日...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odeml2uxi/">
    
    
    
    
    
      
    
    🔻这是这些天美国大选讨论中，美国网友回忆的“美国梦”。<!-- raw HTML omitted -->🔻图1（1947年），俄克拉荷马州塔尔萨，参加派对的青少年。<!-- raw HTML omitted -->🔻图2（1947年），家庭主妇与一周的日用品合影。她总共花了 12.50 美元（不包括牛奶）购买日用品。在这样的预算下，她能够养活自己、丈夫、四岁的双胞胎和他们的猫。<!-- raw HTML omitted -->🔻图3（1954年），一个福特工人家庭。<!-- raw HTML omitted -->🔻图4（1959年），一个美国家庭。<!-- raw HTML omitted -->🔻1947年的12.5美元差不多相当于现在的120-140美元，参与讨论的每个美国人都在骂美国政府。<!-- raw HTML omitted -->🔻美国为什么会这样？第二次冲击卡脖子了？<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#美国大选#<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containe">https://m.weibo.cn/search?containe</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODeQnc0fI">🔻……哦天啊。 包容万物恒河水的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odeqnc0fi/">
    
    
    
    
    
      
    
    🔻……哦天啊。 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->包容万物恒河水的微博视频<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/nLdGm0DNlx08j4MzBoxq01041200bZ8o0E010.mp4?label=m">https://f.video.weibocdn.com/o0/nLdGm0DNlx08j4MzBoxq01041200bZ8o0E010.mp4?label=m</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODf7knA9l">🔻最新消息 - 华邮宣布：“不会为任何总统候选人背书。”🔻糊涂啊，忠诚不绝对，就是绝对不忠诚。#美国大选# [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odf7kna9l/">
    
    
    
    
    
      
    
    🔻最新消息 - 华邮宣布：“不会为任何总统候选人背书。”<!-- raw HTML omitted -->🔻糊涂啊，忠诚不绝对，就是绝对不忠诚。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#美国大选#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODffgyf0i">🔻黎巴嫩监控视频：以军空袭提尔城，命中了拉希迪耶营地的海滩，什么都没打中。🔻所以有时候远距离看到类似这样的火光视频，并不代表就打中了什么“弹药库”...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odffgyf0i/">
    
    
    
    
    
      
    
    🔻黎巴嫩监控视频：以军空袭提尔城，命中了拉希迪耶营地的海滩，什么都没打中。<!-- raw HTML omitted -->🔻所以有时候远距离看到类似这样的火光视频，并不代表就打中了什么“弹药库”，也可能是以军弹药自带的效果，以军的宣传老这么说，满地都是它们打中的“弹药库”。<!-- raw HTML omitted -->🔻via al-mayadeen 电视台<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODfXpxWST">🔻受潭美影响，菲律宾八打雁省已有 47 人死 亡。据菲律宾社会福利与发展部称，菲律宾已有超过 330 万人受灾，其中有 28.8 万人（包括 7.5 万个家庭）仍住在 33...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odfxpxwst/">
    
    
    
    
    
      
    
    🔻受潭美影响，菲律宾八打雁省已有 47 人死 亡。据菲律宾社会福利与发展部称，菲律宾已有超过 330 万人受灾，其中有 28.8 万人（包括 7.5 万个家庭）仍住在 3300 个政府庇护所中。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#台风潭美进入24小时警戒线#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/ODg116xmT">被黎巴嫩抵抗组织打死的，就是这个案件的凶 手。 查看图片 - 转发 @包容万物恒河水:&amp;ensp;🔻约旦西岸非法定居点最危险、最暴力的非法定居者之一舒瓦艾尔-本-纳...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-odg116xmt/">
    
    
    
    
    
      
    
    被黎巴嫩抵抗组织打死的，就是这个案件的凶 手。 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->查看图片<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@包容万物恒河水<!-- raw HTML omitted -->: 🔻约旦西岸非法定居点最危险、最暴力的非法定居者之一舒瓦艾尔-本-纳坦（Shoval Ben Natan）作为应征入伍的以军，刚刚在黎巴嫩南部被打死。<!-- raw HTML omitted -->🔻他是本 &hellip;
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

